ClinicalTrials.gg
Not yet recruitingNCT07557524VACUpdated Nov 5, 2026

Pulsed High Intensity Laser Versus Negative Pressure Therapy On Neuropathic Ulcers

An interventional study of Laser therapy and Negative pressure therapy is applied to the negative pressure group in Neuropathic Ulcers, sponsored by Cairo University. Not yet recruiting at 1 site in Egypt. Open to participants aged 40 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Cairo University · Not applicable, Interventional, and Treatment

How we know

Updated Nov 5, 2026Start date movedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
40 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies in Ulcer with a site in Egypt — 3 open to participants now, 3 under way, 1 of them phase 3. Ulcer · Egypt.

Planned enrollment
5th of 20
70 · median 38
Started
2026
with 1 other
No phase
14 of 22
1 open now
Registered
21st of 22
by date
Lead sponsor
6 of 22
Cairo University

Among the 22 studies in Ulcer with a site in Egypt, this one is the 5th largest by planned enrollment of the 20 interventional ones that give a count, is one of 2 that started in 2026, is one of 14 with no phase, and was the 21st registered.

Ulcer

360 studies on the registry are indexed under Ulcer; 61 are open to participants now.

Browse Ulcer studies →

Open to participants now

3 of the 22 studies in Ulcer with a site in Egypt are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →

Who these studies take

Of the 39 Ulcer studies recruiting now, 30 (77%) set no upper age limit and 3 (8%) stop at 75 or younger; 3 take children under 18; 5 take healthy volunteers.

This study: 40 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Ulcer with a site in Egypt, or all of them as a file.
02

Study summary

the study comparess between laser therapy and vac to decide which on is superior

Read the detailed description

the vac will be used for 4 weeks the laser will be used for 3 session per weak for four weaks

03

Conditions studied

  • Neuropathic Ulcers

Browse trials for

04

Who can participate

Ages eligible
40 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

-

The subject selection will be according to the following criteria:

  1. Ages of patients will be ranged from 40 to 60 years.
  2. All patients have grade one, two and three neuropathic wound.
  3. Both male and female are included.

Exclusion criteria

Exclusion Criteria:

The potential participants will be excluded if they meet one of the following criteria:

  1. Patient with untreated osteomyelitis.
  2. Patients with active bleeding.
  3. Patients with prescription of anticoagulant.
  4. Patients with associated bone fractures.
  5. Patients with .
  6. Patients with diminished cognitive capacity.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
70 participants (estimated)

Study arms

  • Active comparator
    laser group

    In this group of the study, will receive pulsed High intensity laser therapy (GaAs laser) in addition to traditional wound management for 3 sessions per week for four weeks at 980 nm laser irradiation at 15 W at 20hz laser emission potently stimulates defens in production in keratinocytes via ROS-mediated pathways. While these in vitro parameters highlight mechanistic efficacy, clinical translation for chronic wounds requires: Non-contact scanning techniques

    Device: Laser therapy

  • Active comparator
    negative pressure wound therapy

    In this group of the study, will receive negative pressure wound therapy in addition to traditional wound management for four weeks.

    Device: Negative pressure therapy is applied to the negative pressure group

Interventions

  • DeviceLaser therapy

    Pulsed high intensity laser therapy is applied to wound bed

  • DeviceNegative pressure therapy is applied to the negative pressure group

    It will be applied to patients with chronic wound

06

What researchers measure

Primary outcomes

  1. wound surface area

    imitoMeasure Mobil application: The ImitoMeasure app is a noncontact digital planimetry application that measures wound surface area and offers an advantage over other methods. The introduction of smartphones with high-definition cameras. These devices are not only portable and inexpensive, but they also provide the convenience of on-the-spot assessments.

    Time frame: one month

Secondary outcomes

  1. qulity of life

    Wound quality of life questionnaire The Wound-QoL questionnaire has been tested in a previous study, indicating that it is a reliable and valid tool for assessing HRQoL in chronic wounds. It contains 17 items, each with a 5-point Likert scale (0 = not at all, 4 = very much).

    Time frame: one month and three months

07

Study locations

1 site
  • ELshiek Zayed spicilized hospital
    Giza, Egypt
08

References and documents

Publications

  • Tang Y, Liu L, Jie R, Tang Y, Zhao X, Xu M, Chen M. Negative pressure wound therapy promotes wound healing of diabetic foot ulcers by up-regulating PRDX2 in wound margin tissue. Sci Rep. 2023 Sep 27;13(1):16192. doi: 10.1038/s41598-023-42634-9. PubMed 37758743 ↗
  • Leclere FM, Puechguiral IR, Rotteleur G, Thomas P, Mordon SR. A prospective randomized study of 980 nm diode laser-assisted venous ulcer healing on 34 patients. Wound Repair Regen. 2010 Nov-Dec;18(6):580-5. doi: 10.1111/j.1524-475X.2010.00637.x. Epub 2010 Oct 19. PubMed 20958856 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Feb 2027, 3 months later.

Of 44 non-industry interventional studies with no phase under Ulcer, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 64. This study's planned 3 months is below that.

Counting every sponsor, half of 69 studies reached it within 25 months; a quarter within 10 and three quarters within 43.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 5, 2026: start Apr 2026 → Nov 2026, primary completion Sep 2026 → Feb 2027 and completion Sep 2026 → Feb 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 23, 2026
First posted
Apr 29, 2026
StartEst.
Nov 12, 2026was Apr 2026
Primary completionEst.
Feb 28, 2027was Sep 2026
CompletionEst.
Feb 28, 2027was Sep 2026
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Apr 30, 2026→Nov 12, 2026
Nov 5, 2026
Primary completion
Sep 30, 2026→Feb 28, 2027
Nov 5, 2026
Study completion
Sep 30, 2026→Feb 28, 2027
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    Start date Apr 30, 2026→Nov 12, 2026
    Primary completion Sep 30, 2026→Feb 28, 2027
    Study completion Sep 30, 2026→Feb 28, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07557524
Lead sponsor
Cairo University
Responsible party
Yomna El-Rafaie (Physiotherapy practitioner, Cairo University) — Principal investigator
First posted
Apr 29, 2026
Start date
Nov 12, 2026 (estimated)
Primary completion
Feb 28, 2027 (estimated)
Completion
Feb 28, 2027 (estimated)
Last update
Nov 5, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion